Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Viva Biotech to Pay $368 Million to Acquire Controlling Stake in China CDMO

publication date: Aug 10, 2020

Viva Biotech, a Shanghai structure-based drug discovery CRO, will pay $368 million to acquire an 80% stake in Zhejiang Langhua Pharma, a CDMO and API company. Viva said the acquisition will add services that transform Viva into a one-stop biotech CRO platform. Viva offers its structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide via two models: cash-for-service (CFS) or equity-for service (EFS), which includes investment and incubation services for high-potential biotech start-ups. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital